An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 3 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient’s Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS)
The primary objective of this study is to evaluate the efficacy of DA-1229 versus placebo in reducing the progression of aortic valve calcification as measured by cardiac computed tomography (CT) aortic valve calcium score (using the Agatston method and expressed in arbitrary units [AU]) over 2 years (104 weeks) of therapy in subjects with mild to moderate aortic stenosis.
Primary Investigator: Eugene Chung